AU2013236960B2 - Method for treating gynecological diseases - Google Patents

Method for treating gynecological diseases Download PDF

Info

Publication number
AU2013236960B2
AU2013236960B2 AU2013236960A AU2013236960A AU2013236960B2 AU 2013236960 B2 AU2013236960 B2 AU 2013236960B2 AU 2013236960 A AU2013236960 A AU 2013236960A AU 2013236960 A AU2013236960 A AU 2013236960A AU 2013236960 B2 AU2013236960 B2 AU 2013236960B2
Authority
AU
Australia
Prior art keywords
administration
pharmaceutical composition
vaginal
active metabolite
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013236960A
Other languages
English (en)
Other versions
AU2013236960A1 (en
Inventor
Valerie Boujac
Jean-Pierre Gotteland
Ernest Loumaye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Preglem SA
Original Assignee
Preglem SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem SA filed Critical Preglem SA
Publication of AU2013236960A1 publication Critical patent/AU2013236960A1/en
Application granted granted Critical
Publication of AU2013236960B2 publication Critical patent/AU2013236960B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2013236960A 2012-03-23 2013-03-22 Method for treating gynecological diseases Ceased AU2013236960B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261614785P 2012-03-23 2012-03-23
US61/614,785 2012-03-23
EP12160956.4A EP2641602A1 (en) 2012-03-23 2012-03-23 Method for treating gynecological diseases
EP12160956.4 2012-03-23
PCT/IB2013/052274 WO2013140372A1 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Publications (2)

Publication Number Publication Date
AU2013236960A1 AU2013236960A1 (en) 2014-09-25
AU2013236960B2 true AU2013236960B2 (en) 2017-11-23

Family

ID=45976689

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013236960A Ceased AU2013236960B2 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Country Status (18)

Country Link
US (1) US10441534B2 (enExample)
EP (3) EP2641602A1 (enExample)
JP (2) JP2015514700A (enExample)
KR (1) KR20140138824A (enExample)
CN (1) CN104203246A (enExample)
AU (1) AU2013236960B2 (enExample)
CA (1) CA2864073A1 (enExample)
CO (1) CO7111317A2 (enExample)
EA (1) EA031488B1 (enExample)
GE (1) GEP201706696B (enExample)
HK (1) HK1199827A1 (enExample)
MX (1) MX369520B (enExample)
MY (1) MY172530A (enExample)
NZ (1) NZ630011A (enExample)
SG (1) SG11201404921QA (enExample)
TW (2) TW201832767A (enExample)
WO (1) WO2013140372A1 (enExample)
ZA (1) ZA201407575B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017165707A1 (en) * 2016-03-24 2017-09-28 Juniper Pharmaceuticals, Inc. Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures
PT3523315T (pt) 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095418A1 (en) * 2008-01-29 2009-08-06 Erin Gainer Use of ulipristal for treating uterine fibroids
US20100190758A1 (en) * 2007-04-20 2010-07-29 Prelem S.A. Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
EP0180264A1 (en) 1984-10-12 1986-05-07 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
JP5017109B2 (ja) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
ES2648640T3 (es) * 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190758A1 (en) * 2007-04-20 2010-07-29 Prelem S.A. Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding
WO2009095418A1 (en) * 2008-01-29 2009-08-06 Erin Gainer Use of ulipristal for treating uterine fibroids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIETZ A. et al, Fertility and Sterility, 2009, Vol. 92(3), supplement S60, 0-206 *
TOMIC V. et al, Oral micronized progesterone combined with vaginal progesterone gel for luteal support, Gynecological Endocrinology, 2011, Vol. 27(12), pg. 1010-1013 *

Also Published As

Publication number Publication date
EA201491614A1 (ru) 2015-01-30
WO2013140372A1 (en) 2013-09-26
TW201400121A (zh) 2014-01-01
TW201832767A (zh) 2018-09-16
AU2013236960A1 (en) 2014-09-25
NZ630011A (en) 2016-12-23
EP2827873A1 (en) 2015-01-28
SG11201404921QA (en) 2014-10-30
CA2864073A1 (en) 2013-09-26
EP3363500A1 (en) 2018-08-22
MY172530A (en) 2019-11-29
JP2015514700A (ja) 2015-05-21
US20150038476A1 (en) 2015-02-05
US10441534B2 (en) 2019-10-15
CN104203246A (zh) 2014-12-10
HK1199827A1 (en) 2015-07-24
GEP201706696B (en) 2017-07-10
JP2018109025A (ja) 2018-07-12
MX369520B (es) 2019-11-11
ZA201407575B (en) 2015-12-23
CO7111317A2 (es) 2014-11-10
EA031488B1 (ru) 2019-01-31
MX2014011487A (es) 2015-01-12
KR20140138824A (ko) 2014-12-04
EP2641602A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
CA2818468C (en) Treatment of pain associated with dislocation of basal endometrium
US10441534B2 (en) Method for treating gynecological diseases
EP3518933A2 (en) Methods of treating uterine fibroids and endometriosis
US20100204146A1 (en) Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women
AU2012282061B2 (en) Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2968367A1 (en) Method for scheduling ovulation
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
JP2019034969A (ja) プロゲステロン受容体アンタゴニスト剤形
US20190262361A1 (en) Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids
US20260115203A1 (en) Low-dose mifepristone for the treatment of endometriosis associated pain
JP2019524846A (ja) 子宮内膜症の治療のための投与レジメン
HK1188939A (zh) 基底子宫内膜异位相关疼痛的治疗

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired